Study
Chromium Supplementation May Improve Insulin Resistance in Older Adults with Type 2 Diabetes
A study found that taking 400 micrograms of chromium daily can reduce insulin resistance in adults over 40 with type 2 diabetes.
NutritionDiabetes & Blood Sugar
Summary
In plain language
Recent research has shown that supplementing with chromium can help improve insulin resistance in older adults with type 2 diabetes. The study involved adults over the age of 40 who took 400 micrograms of chromium daily for eight weeks. While the chromium supplementation did not significantly lower fasting blood glucose levels, it did result in a noticeable reduction in insulin resistance. This finding is important because managing insulin resistance can help prevent further complications associated with diabetes. Seniors with type 2 diabetes may want to discuss with their healthcare providers whether chromium supplementation could be a beneficial addition to their diabetes management plan.
Details
Use the full description to understand the study design, methods, and the limits of the findings.
This study was a controlled trial where participants with type 2 diabetes were given chromium or a placebo for eight weeks. Researchers measured cholesterol and insulin resistance, finding improvements in those taking chromium.
The study found a significant reduction in total cholesterol and insulin resistance in the chromium group.
No significant changes were observed in fasting blood glucose or body weight.
The study had a small sample size, and results may differ with larger groups or higher doses.
Seniors should discuss adding chromium supplements with their healthcare providers, especially if managing diabetes.
Full Study
Open the original publication for the complete methods, outcomes, and source material.
Chromium Supplementation May Improve Insulin Resistance in Older Adults with Type 2 Diabetes
Published March 2026
Opens at the publisher · external site · may require institutional access
Research Quality Score
Assessment
The study is a high-quality randomized controlled trial with strong bias control and statistical integrity. It is well-documented and transparent, with no conflicts of interest. However, its direct relevance to seniors is limited as the participant age range starts at 40.
Category Breakdown
| Category | Score | Rating |
|---|---|---|
| Study Design / Evidence Level | 10.0/10 | |
| Bias & Methods | 10.0/10 | |
| Statistical Integrity | 10.0/10 | |
| Transparency | 10.0/10 | |
| Conflict of Interest Disclosure | 10.0/10 | |
| Replication / External Validation | 5.0/10 | |
| Relevance to Seniors | 5.0/10 | |
| Journal Quality | 10.0/10 |
Additional Notes
The study's findings are robust, but further research focusing specifically on the senior population would enhance its applicability to adults aged 60+.
Treatments Evaluated in This Research
Review the interventions studied here and compare them against the broader treatment library.
Take the next step
Build a personalized plan using research-backed studies, conditions, and treatments.